SCHEMBL5370157

SCHEMBL5370157

CCc1ccc(C=C2C(=O)Nc3ccc(Br)c(C)c32)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.58
ERBB2 P04626 2/20 0.44
KMT2A Q03164 7/20 0.39
MEN1 O00255 5/20 0.39
ALPL P05186 1/20 0.39
HSP90AA1 P07900 1/20 0.39
ALPI P09923 1/20 0.39
ALPG P10696 1/20 0.39
G6PD P11413 1/20 0.39
RAF1 P04049 1/20 0.37
POLB P06746 5/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
ATM Q13315 1/20 0.36
PKM P14618 2/20 0.34
TNFRSF1A P19438 1/20 0.34
KDM4E B2RXH2 2/20 0.33
RET P07949 2/20 0.33
PDGFRB P09619 2/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5357849 0.85 MEN1 (0.55) EGFRERBB2KMT2AMEN1ALPL
SCHEMBL5361220 0.85 ERBB2 (0.47) EGFRERBB2KMT2AMEN1ALPL
SCHEMBL5368564 0.84 MEN1 (0.50) EGFRERBB2KMT2AMEN1ALPL
SCHEMBL7138194 0.82 EGFR (0.51) EGFRERBB2KMT2AMEN1ALPL
SCHEMBL5363130 0.81 ERBB2 (0.67) EGFRERBB2KMT2AMEN1ALPL
SCHEMBL5376938 0.78 ERBB2 (0.43) EGFRERBB2KMT2AMEN1ALPL
SCHEMBL7137405 0.77 IGF1R (0.45) ERBB2KMT2AMEN1RAF1MAPT
SCHEMBL7138976 0.77 POLB (0.41) ERBB2RAF1POLBMAPTRET
SCHEMBL5367226 0.76 PTPN1 (0.44) KMT2AMEN1POLBALDH1A1MAPT
SCHEMBL5364403 0.75 KMT2A (0.56) KMT2AMEN1ALPLALPIALPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK EGFR 286/4885ERBB2 19/4885KMT2A 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.